Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 17 studies | 33% ± 12% | |
lung | 16 studies | 33% ± 15% | |
brain | 12 studies | 29% ± 10% | |
eye | 9 studies | 33% ± 18% | |
kidney | 8 studies | 30% ± 10% | |
intestine | 8 studies | 34% ± 17% | |
liver | 6 studies | 41% ± 23% | |
bone marrow | 5 studies | 33% ± 12% | |
lymph node | 5 studies | 34% ± 14% | |
placenta | 4 studies | 37% ± 13% | |
uterus | 4 studies | 39% ± 18% | |
pancreas | 4 studies | 26% ± 13% | |
adrenal gland | 3 studies | 26% ± 3% | |
skin | 3 studies | 20% ± 3% | |
thymus | 3 studies | 52% ± 20% | |
breast | 3 studies | 30% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 7324.93 | 459 / 459 | 100% | 194.06 | 1118 / 1118 |
lung | 100% | 6038.54 | 578 / 578 | 100% | 142.01 | 1155 / 1155 |
brain | 100% | 4623.18 | 2638 / 2642 | 100% | 137.39 | 705 / 705 |
uterus | 100% | 5845.53 | 170 / 170 | 100% | 167.11 | 458 / 459 |
ovary | 100% | 6691.93 | 180 / 180 | 100% | 123.72 | 429 / 430 |
bladder | 100% | 5437.10 | 21 / 21 | 100% | 152.18 | 502 / 504 |
esophagus | 100% | 4858.31 | 1445 / 1445 | 99% | 119.13 | 182 / 183 |
thymus | 100% | 5033.18 | 653 / 653 | 99% | 108.61 | 601 / 605 |
prostate | 100% | 4966.13 | 245 / 245 | 99% | 89.97 | 498 / 502 |
stomach | 100% | 3899.01 | 359 / 359 | 99% | 131.78 | 283 / 286 |
kidney | 100% | 5874.56 | 89 / 89 | 99% | 90.70 | 891 / 901 |
skin | 100% | 7035.50 | 1809 / 1809 | 99% | 216.46 | 465 / 472 |
pancreas | 100% | 2957.98 | 328 / 328 | 98% | 103.63 | 175 / 178 |
intestine | 100% | 5790.48 | 966 / 966 | 98% | 153.16 | 518 / 527 |
adrenal gland | 100% | 7707.00 | 258 / 258 | 98% | 89.18 | 225 / 230 |
liver | 100% | 3222.08 | 226 / 226 | 96% | 64.30 | 391 / 406 |
adipose | 100% | 6901.69 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5445.31 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 163.25 | 29 / 29 |
muscle | 100% | 4510.64 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 7155.96 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 125.01 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 80.13 | 1 / 1 |
heart | 98% | 3516.34 | 840 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 90% | 6097.66 | 838 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 90% | 75.68 | 72 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0006338 | Biological process | chromatin remodeling |
GO_0031507 | Biological process | heterochromatin formation |
GO_0048511 | Biological process | rhythmic process |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_0000792 | Cellular component | heterochromatin |
GO_0000791 | Cellular component | euchromatin |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005637 | Cellular component | nuclear inner membrane |
GO_0005635 | Cellular component | nuclear envelope |
GO_0061793 | Cellular component | chromatin lock complex |
GO_0090734 | Cellular component | site of DNA damage |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0005721 | Cellular component | pericentric heterochromatin |
GO_0000779 | Cellular component | condensed chromosome, centromeric region |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0000785 | Cellular component | chromatin |
GO_0005819 | Cellular component | spindle |
GO_0005634 | Cellular component | nucleus |
GO_0035064 | Molecular function | methylated histone binding |
GO_0019899 | Molecular function | enzyme binding |
GO_0019904 | Molecular function | protein domain specific binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0001221 | Molecular function | transcription coregulator binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005515 | Molecular function | protein binding |
GO_1990226 | Molecular function | histone methyltransferase binding |
Gene name | CBX3 |
Protein name | Chromobox protein homolog 3 (HECH) (Heterochromatin protein 1 homolog gamma) (HP1 gamma) (Modifier 2 protein) Chromobox 3 Chromobox homolog 3 (HP1 gamma homolog, Drosophila) (Coiled-coil domain containing 32, isoform CRA_c) Chromobox 3 (Chromobox homolog 3 (HP1 gamma homolog, Drosophila), isoform CRA_b) |
Synonyms | hCG_1999239 CCDC32 tcag7.173 hCG_1745364 |
Description | FUNCTION: Seems to be involved in transcriptional silencing in heterochromatin-like complexes. Recognizes and binds histone H3 tails methylated at 'Lys-9', leading to epigenetic repression. May contribute to the association of the heterochromatin with the inner nuclear membrane through its interaction with lamin B receptor (LBR). Involved in the formation of functional kinetochore through interaction with MIS12 complex proteins. Contributes to the conversion of local chromatin to a heterochromatin-like repressive state through H3 'Lys-9' trimethylation, mediates the recruitment of the methyltransferases SUV39H1 and/or SUV39H2 by the PER complex to the E-box elements of the circadian target genes such as PER2 itself or PER1. Mediates the recruitment of NIPBL to sites of DNA damage at double-strand breaks (DSBs) . . |
Accessions | A4D177 C9JMM0 ENST00000456948.5 Q13185 ENST00000396386.7 ENST00000409747.5 ENST00000337620.8 B8ZZ43 S4R2Y4 ENST00000462165.2 |